MedTrace Logo

Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid Malignancies

NCT07782346 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2026-08-26

No results posted yet for this study

Summary

Phase I trial, Multiple centers, open-label, non-randomized single-arm study

Conditions

  • Advanced Solid Malignancies

Interventions

DRUG

Liposomal Irinotecan Plus Cisplatin

Liposomal irinotecan and cisplatin are administered intravenously on Days 1 and 15 of each 28-day cycle.

Sponsors & Collaborators

  • China Medical University Hospital

    collaborator OTHER

  • National Taiwan University Hospital

    collaborator OTHER

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • Mackay Memorial Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • Taichung Veterans General Hospital

    collaborator OTHER

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Hui-Jen Tsai, MD, PhD · National Health Research Institutes, Taiwan

  • Li-Yaun Bai, MD, PhD · China Medical University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2030-12-31
Completion
2032-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07782346 on ClinicalTrials.gov